Brelor ( Ticagrelor ) is a P2Y12 inhibitor antiplatelet drug. Brelor is indicated to reduce the risk of cardiovascular death, myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS). Brelor also reduces the risk of stent thrombosis in patients who have been stented for angioplasty.
In order to achieve inalienable right of every Iranian patient to take high quality medicine, Kimiara Company has produced its Ticagrelor under the brand name Brelor, based on the highest international standards to support patients. API and formulations of Ticagerlor are supplied from the strongest pharmaceutical company in manufacturing API in the world called MSN. The manufacturing line of Ticagrelor in this company is approved by the USFDA and Europe GMP. MSN has No. 1 ranking in USA DMF filings with worldwide expansion and introduced 17 first in the world generics.
According to another proved quality index, efficacy and safety of Brelor has been demonstrated to be bioequivalent with originator brand Brillinta manufactured by AstraZeneca, based on FDA requirements in bioequivalence studies. In consequence, high quality Brelor is a reliable alternative to originator brand in Iran in accordance with API quality, the formulation, manufacturing line and bioequivalence study results of Brelor with originator.